UK may revise rules on "specials"
This article was originally published in Scrip
The UK medicines regulator, the MHRA, wants to iron out the rules governing the manufacture and importation of unlicensed medicines. A recent consultation document outlines regulatory challenges at the fringes of the pharmaceutical market and possible shapes for new legislation in this area.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.